Former AdvaMedDx Board Chair Joins Bruker’s Governing Body

Bruker Corporation has appointed Thierry L. Bernard to its Board of Directors. The international life sciences tools and diagnostics industry executive has decades of relevant leadership, strategic, and operational experience.

“Bruker is delighted that Thierry is joining our board,” Bruker Corporation Chairman/President/CEO Frank H. Laukien stated. “I have admired his track record, astute strategic initiatives, and execution for many years, and I am convinced that Thierry will be an excellent addition to our Board of Directors as we further develop our leadership position in life science research, biopharma, and diagnostic solutions in the post-genomic era, and aim for profitable growth and rapid margin expansion to enhance stakeholder value.”

Bernard is currently CEO of QIAGEN N.V. He joined the company in 2015 to lead its growing molecular diagnostics business and was promoted to the top spot in 2019. He has announced his intention to step down as CEO upon the appointment of a successor.

Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, including as corporate vice president for Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in several other leading international companies.

In 2023, Bernard was named AdvaMedDx board chair and joined Neogen Corporation’s governing body in 2024. He has earned degrees and certifications from Sciences Po Paris, the London School of Economics, the College of Europe, Harvard Business School, and Centro de Comercio Exterior de Barcelona.

“I am very pleased to join Bruker’s Board of Directors. I have long admired its contributions to scientific research and improving patient outcomes,” Bernard commented. “Bruker’s technologies and global footprint position it well to enable a deeper understanding of biology to support more precise diagnostics, more effective therapies, and ultimately better healthcare. I look forward to supporting its continued development and commitment to long-term value creation.”

Bruker enables scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of life. Bruker’s scientific instruments and analytical and diagnostic solutions allow scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with its customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of artificial intelligence. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.